Zydus Cadila aims to launch at least two more novel drugs out of the 20 currently under discovery research programmes to become successful by 2020. It is currently working in the areas of metabolic disorders, oncology and inflammatory disorders. The company is planning to finance its drug discovery programmes, through internal resources.
A part of the Zydus Group, Cadila Healthcare had received regulatory approval to market its diabetes drug, Lipaglyn, in India last week. It expects the drug to be a blockbuster and clock over $1 billion sales a year when sold globally.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1669.20 |
| Dr. Reddys Lab | 1233.00 |
| Cipla | 1232.25 |
| Zydus Lifesciences | 937.65 |
| Lupin | 2328.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: